Abstract | OBJECTIVE: DESIGN: A post hoc analysis was conducted using data from the European Stroke Prevention Study 2. Rates of annual strokes and vascular events were determined for the aspirin plus extended-release dipyridamole group (n = 1650) and the aspirin-only group (n = 1649), and were stratified by risk subgroup and univariate risk factors. Stroke models from the Framingham Study and the Stroke Prognostic Instrument II were applied to subjects in the European Stroke Prevention Study 2 to categorize patients into risk groups. RESULTS: CONCLUSION:
Aspirin plus extended-release dipyridamole is more effective than aspirin alone at preventing stroke, and the difference in efficacy increases in higher-risk patients.
|
Authors | Ralph L Sacco, Juhani Sivenius, Hans-Christoph Diener |
Journal | Archives of neurology
(Arch Neurol)
Vol. 62
Issue 3
Pg. 403-8
(Mar 2005)
ISSN: 0003-9942 [Print] United States |
PMID | 15767505
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Delayed-Action Preparations
- Dipyridamole
- Aspirin
|
Topics |
- Adult
- Aged
- Aspirin
(administration & dosage)
- Delayed-Action Preparations
(administration & dosage)
- Dipyridamole
(administration & dosage)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- Multicenter Studies as Topic
- Randomized Controlled Trials as Topic
- Risk Factors
- Secondary Prevention
- Stroke
(drug therapy, epidemiology, prevention & control)
|